Abstract: The present intervention identifies the antiglycating inhibitors from a series of carbazole-linked 1,2,3 triazole derivatives through in vitro MGO-mediated glycating BSA model. Derivatives 12, and 13 established a remarkable antiglycation activity at the receptor level in human monocytes. These compounds were found non-toxic, and possess the potential to halt AGE-RAGE/ROS-mediated NF-kB-dependent COX-2, and its proinflammatory product, PGE2, production in monocytes. Hence, carbazole-linked 1,2,3 triazole derivatives provide treatment modalities to delay or prevent the onset of late diabetic micro- and macro-vascular complications in diabetic patients.

Abstract: The present intervention identifies the antiglycating inhibitors from a series of carbazole-linked 1,2,3 triazole derivatives through in vitro MGO-mediated glycating BSA model. Derivatives 12, and 13 established a remarkable antiglycation activity at the receptor level in human monocytes. These compounds were found non-toxic, and possess the potential to halt AGE-RAGE/ROS- mediated NF- kB-dependent COX-2, and its proinflammatory product, PGE2, production in monocytes. Hence, carbazole-linked 1,2,3 triazole derivatives provide treatment modalities to delay or prevent the onset of late diabetic micro- and macro-vascular complications in diabetic patients.

Abstract: The present invention relates to the effects of Physalis minima L. methanolic extract on dyslipidemia and insulin resistance in insulin resistant high-fat diet-induced obese rats without any systemic toxicities. The extract reversed the dyslipidemia and insulin resistance in high-fat diet-induced obese rats.

Abstract: (?)3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan (ambrox) is a strong aromatic compound used widely in a variety of perfumery applications and is highly prized for its musky odor. We report novel polar metabolites of (?)3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan prepared by a novel process of microbial fermentation using a fungi, Fusarium lini, of unique structures that would be difficult to predict opening up the possibilities of their chemical synthesis. The polar metabolites discovered have stronger aromatic characteristics and offer a new highly prized odiferous characteristic quite different from that of the parent compound and thus can be used in the preparation of perfumes, odor-masking and other odor-management applications.

Abstract: Treatment of leishmaniasis in animals and humans using the methanolic extract of Physalis minima in petrolatum is described.

Abstract: Method of producing ?5-Tibolone (C21H28O2), 6?-Hydroxy-?4-tibolone (C21H28O3), 6?-Hydroxy-?4-tibolone (C21H28O3), 15?-Hydroxy-?4-tibolone (C21H28O3), 6?-Hydroxy-?1,4-tibolone (C21H28O3) and 6?-Methoxy-?4-tibolone (C22H30O3) contacting tibolone with Gibberella fujikuroi (ATCC 10704) is reported.

Abstract: Three new acylphloroglucinols, myrtucommulone-D (Compound 1), myrtucommulone-E (Compound 2), myrtucommulone-C (Compound 3), and a known acyphloroglucinol myrtucommulone B (Compound 4) were isolated from a methanolic extract of Myrtus communis L. The structures of compounds 1, 2 and 4 were also unambiguously determined by single X-ray diffraction analysis. The compounds 1-4 were found to be more potent ?-glucosidase inhibitors than the clinically used standards, acarbose and deoxynojirimycin. The compound 3 exhibited the highest activity among all the acylphloroglucinols, with an IC50=35.4±1.15 ?M. The compounds 1 and 2 also exhibited strong antibacterial activities.

Abstract: The invention relates to novel isoxylitones and their use as anticonvulsant and in the treatment of a variety of disorders.

Abstract: The invention relates to novel isoxylitones and their use as anticonvulsant and in the treatment of a variety of disorders